Previous 10 | Next 10 |
Investing legend Peter Lynch coined the term "10-bagger" to describe a stock that delivers a tenfold return. Relatively few stocks ever earn the moniker. But a couple of marijuana stocks have done just that and then some. Both of these stocks have turned an initial investment of $10,000 into ...
It's no secret that cannabis is considered one of the hottest investment trends of this generation on Wall Street. Although selling a processed plant isn't exactly what you might call innovative, the black market for global weed sales generates tens of billions of dollars each year. This means...
This edition of our ongoing Better Buy series pits two marijuana stocks -- GW Pharmaceuticals (NASDAQ: GWPH) and Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) -- against each other. Rather than growing plants to sell, both companies are taking the more regulated path of developing dru...
GWPH stock is having its worst one-day fall in the past few months despite GW Pharmaceuticals (NASDAQ:GWPH) posting better-than-expected revenue from its flagship product, Epidiolex. Solid Earnings Despite the troubles of the past few months, some companies in the cannabis industry have...
Shares of GW Pharmaceuticals (NASDAQ: GWPH) , a biopharmaceutical company focused on cannabinoids, are sinking in response to a relatively good third-quarter earnings report. Despite beating consensus estimates on the top and bottom lines after the bell on Tuesday, the pharma stock has fall...
Fluidigm (NASDAQ: FLDM ) -31% on Q3 results . More news on: Fluidigm Corporation, Plantronics, Inc., Amneal Pharmaceuticals, Inc., Stocks on the move, Read more ...
Image source: The Motley Fool. GW Pharmaceuticals PLC (NASDAQ: GWPH) Q3 2019 Earnings Call Nov 5, 2019 , 4:30 p.m. ET Operator Continue reading
GW Pharmaceuticals ' (NASDAQ: GWPH) launch of cannabidiol (CBD) drug Epidiolex has gone exceptionally well so far. The biotech has trounced sales estimates quarter after quarter. Investors were hoping for continued momentum when GW reported its third-quarter results after the market closed...
GW Pharmaceuticals plc (GWPH) Q3 2019 Earnings Conference Call November 5, 2019 4:30 PM ET Company Participants Stephen Schultz - Vice President of Investor Relations Justin Gover - Chief Executive Officer Darren Cline - U.S. Chief Commercial Officer Chris Tovey - Chief Operati...
GW Pharmaceuticals (NASDAQ: GWPH ) Q3 results : More news on: GW Pharmaceuticals plc, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
GW Pharmaceuticals Plc Company Name:
GWPH Stock Symbol:
NASDAQ Market:
GW Pharmaceuticals Plc Website:
The key to investing is “Buy low, sell high”. According to that mantra, periods of weakness are the mother’s milk of future gains. When you see them, you know “this is my chance”. It’s the chance to get involved. This is especially true in industries ...
NetworkNewsWire Editorial Coverage : In May 2013, GW Pharma listed on Nasdaq, selling 3.5 million shares at $8.90 each to investors betting that GW was charting a profitable course as a biotech developing new drugs from cannabis-derived compounds. Legal cannabis was only beginning to gain...
Real Brands Inc (OTCMKTS:RLBD) snuck one under the radar late last week, but investors interested in the CBD and Cannabis space should take note. The company filed its Form 10 with the SEC. In this case, it was a voluntary filing because the company does report having over $10 million o...